胆固醇晶体作为NLRP3炎症酶激活在动脉样硬化中的触发器
Mustafa Yalcinkaya1, Alan R Tall2
1Division of Molecular Medicine, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA. my2673@cumc.columbia.edu.
Current atherosclerosis reports
|August 1, 2025
概括
胆固醇晶体 (CCs) 通过激活NLRP3炎症酶来驱动动动脉硬化. 这个过程涉及溶解体损伤,胆固醇贩运和补体激活,导致斑块不稳定和破裂.
科学领域:
- 心血管研究研究心血管研究
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 动脉样硬化是一种慢性炎症性疾病,其特点是动脉中积聚斑块.
- 胆固醇晶体 (CCs) 是动脉样硬化斑块的关键组成部分,并且越来越被认为是强大的炎症刺激.
研究的目的:
- 综合审查胆固醇晶体 (CCs),NLRP3炎症酶激活和动脉样硬化病变之间的复杂关系.
- 阐明CCs触发NLRP3炎症酶激活并导致斑块不稳定性的分子机制.
主要方法:
- 在动脉样硬化中研究CCs和NLRP3炎症组的临床前和临床研究的文献综述.
- 分析参与CC诱导炎症的分子通路,包括溶酶体损伤,细胞胆固醇贩运和补充系统激活.
主要成果:
- CCs促进斑块炎症和不稳定,增加不良心血管事件的风险.
- CCs通过包括 lysosomal 损伤, cathepsin B 释放和 CaMKII / JNK 信号通路在内的机制激活 NLRP3 炎症体.
- 通过CCs激活补体系统,通过影响线粒体功能和反应性氧物种 (ROS) 生产,加剧动脉样硬化.
- 多个CC诱导的途径汇聚在NLRP3炎症酶激活上,推动动脉样硬化斑块的进展.
结论:
- 胆固醇晶体是NLRP3炎症中介性炎症在动脉样硬化中的关键驱动因素.
- 准CC-NLRP3炎症酶相互作用可能为动脉样硬化提供新的治疗策略.
- 需要进一步的研究才能充分理解复杂的相互作用,并将研究结果转化为临床实践.
相关概念视频
01:38Inflammation
55.2K
Overview
55.2K
01:30Atherosclerosis I: Introduction
87
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
87
01:29Cholesterol: Significance and Regulation
689
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Considering cholesterol and...
689
01:26Coronary Artery Disease II: Pathophysiology
38
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
38
01:30Peripheral Artery Disease I: Introduction
33
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
33
01:26Atherosclerosis III: Management
35
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
35